Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pivotal Phase III Study of RHB-204 for the Treatment of Pulmonary Nontuberculous Mycobacteria (NTM) Infections

Trial Profile

A Pivotal Phase III Study of RHB-204 for the Treatment of Pulmonary Nontuberculous Mycobacteria (NTM) Infections

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 29 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clarithromycin/clofazimine/rifabutin (Primary)
  • Indications Nontuberculous mycobacterium infections
  • Focus Registrational; Therapeutic Use
  • Sponsors RedHill Biopharma
  • Most Recent Events

    • 22 May 2023 Status changed from recruiting to discontinued, according to a RedHill Biopharma media release.
    • 28 Apr 2023 According to a RedHill Biopharma media release, In August 2022, the European Commission granted Orphan Drug Designation to RHB-204, which is in an ongoing U.S. Phase 3 study, for the treatment of nontuberculous mycobacteria (NTM) disease, providing 10 years of post-approval EU market exclusivity.
    • 25 Nov 2020 Status changed from planning to recruiting, according to a RedHill Biopharma media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top